A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab.
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2015
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 15 Jun 2013 Planned number of patients changed from 1469 to 1500 as reported by European Clinical Trials Database.
- 18 Nov 2010 Additional locations added as reported by ClinicalTrials.gov.
- 06 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.